Phimo International's (PMI) annual dividend yield for 2022 ranges from 2.1% to 5%.
Philip Morris International (PMI) has a market value of $157 billion, which is almost equivalent to the combined total market value of its two competitors. In addition to its leading cigarette brand, Marlboro, the company also owns the top-notch heat-not-burn brand, IQOS.
Since its launch in 2014, IQOS has amassed a customer base of 19.5 million. The growth in sales of IQOS has offset the decline in sales of cigarettes, which is why PMI's overall sales grew by 3.4% in the first nine months of 2022.
Screenshot of Phimo International's revenue-related data. Source: New York Stock Exchange.
Analysts at the New York Stock Exchange predict that the company's earnings will grow at a rate of 2.8% per year over the next five years. The dividend payout ratio for PMI is expected to reach around 92% by 2022.
At first glance, this seems to be in a favorable position. However, due to the minimal capital required for tobacco companies to operate, this allocation rate should be sustainable in the short term. As PMI's dividend growth rate is lower than its earnings in the coming years, dividends are expected to be very safe.
The most significant factor is that investors can purchase the shares of this tobacco giant at a reasonable valuation and receive a 5% dividend yield. The stock's forward P/E ratio of 18.7 is higher than the tobacco industry's average forward P/E ratio of 13.4.
Special Note: This article does not provide any investment references or suggestions.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
